BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

Panelists discuss how BESPOKE trial results demonstrate significantly improved disease-free survival rates in patients with negative circulating tumor DNA (ctDNA) status compared with those with detectable ctDNA, underscoring its potential as a powerful prognostic biomarker.

EP: 1.The Role of ctDNA in CRC

EP: 2.BESPOKE: Study Design, Efficacy End Points and Methods

EP: 3.Overview of BESPOKE Patient Characteristics

Now Viewing

EP: 4.BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

Recent Videos